Lead candidate BM-3103 (TolaSure® Gel™) now holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations as BioMendics advances the TAMES-02 Phase 2 study (NCT07027345). AKRON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results